Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743

Molecular Cancer Therapeutics

Volumn 1, Issue 14, 2002, Pages 1327-1334

  Kanzaki, Atsuko ^a   Takebayashi, Yuji ^a   Ren, Xiao Qin ^a   Miyashita, Hitoshi ^a   Mori, Shiro ^b   Akiyama, Shin Ichi ^a   Pommier, Yves ^c  

^a TOHOKU UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; COLORING AGENT; DOXORUBICIN; GLYCOPROTEIN P; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TRABECTEDIN; VINCRISTINE;

ARTICLE; CELL CULTURE; CELL SURVIVAL; CHEMICAL MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG RESISTANCE; HUMAN; IC 50; IMMUNOBLOTTING; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; COLORING AGENTS; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MODELS, CHEMICAL; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAHYDROISOQUINOLINES; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0038380364     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rinehart, K. L., Holt, T. G., Fregeau, N. L., Keifer, P. A., Wilson, G. R., Perun, T. J., Jr., Sakai, R., Thompson, A. G., Stroh, J. G., Shield, L. S., et al. Bioactive compounds from aquatic and terrestrial sources. J. Nat. Prod. (Lloydia), 53: 771-792, 1990. (Pubitemid 20334534)
2. Rinehart, K. L. Antitumor compounds from tunicates. Med. Res. Rev., 20: 1-27, 2000. (Pubitemid 30027559)
3. Aune, G., Furuta, T., and Pommier, Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs, 13: 545-555, 2002. (Pubitemid 34816449)
4. D'Incalci, M., Erba, E., Damia, G., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J., and Faircloth, G. T. Unique features of the mode of action of ET-743. Oncologist, 7: 210-216, 2002. (Pubitemid 34651224)
5. Izbicka, E., Lawrence, R., Raymond, E., Eckhardt, G., Faircloth, G., Jimeno, J., Clark, G., and Von Hoff, D. D. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol., 9: 981-987, 1998. (Pubitemid 28496707)
6. Ghielmini, M., Colli, E., Erba, E., Bergamaschi, D., Pampallona, S., Jimeno, J., Faircloth, G., and Sessa, C. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Ann. Oncol., 9: 989-993, 1998. (Pubitemid 28496708)
7. Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998. (Pubitemid 28369184)
8. Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., and Pommier, Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res., 7: 185-191, 2001. (Pubitemid 32110222)
9. Martinez, E. J., and Corey, E. J. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org. Lett., 2: 993-996, 2000.
10. Ryan, D. P., Supko, J. G., Eder, J. P., Seiden, M. V., Demetri, G., Lynch, T. J., Fischman, A. J., Davis, J., Jimeno, J., and Clark, J. W. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res., 7: 231-242, 2001. (Pubitemid 32183024)
11. Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez Lazaro, L., Rosing, H., Jimeno, J. M., and Cvitkovic, E. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol., 19: 1256-1265, 2001. (Pubitemid 32202528)
12. Delaloge, S., Yovine, A., Taamma, A., Riofrio, M.; Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., Marty, M., and Cvitkovic, E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J. Clin. Oncol., 19: 1248-1255, 2001. (Pubitemid 32202527)
13. Verschraegen, C. F., and Glover, K. ET-743 (PharmaMar/NCI/Ortho Biotech). Curr. Opin. Investig. Drugs, 2: 1631-1638, 2001.
14. Sakai, R., Rinehart, K. L., Guan, Y., and Wang, A. H. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc. Natl. Acad. Sci. USA, 89: 11456-11460, 1992.
15. Seaman, F. C., and Hurley, L. H. Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for the dominant role of direct readout via hydrogen bonding. J. Am. Chem. Soc., 120: 13028-13041, 1998. (Pubitemid 29024063)
16. Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry, 35: 13303-13309, 1996. (Pubitemid 26349423)
17. Zewail-Foote, M., and Hurley, L. H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem., 42: 2493-2497, 1999. (Pubitemid 29344290)
18. Zewail-Foote, M., and Hurley, L. H. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc., 123: 6485-6495, 2001. (Pubitemid 32916442)
19. Martinez, E. J., Owa, T., Schreiber, S. L., and Corey, E. J. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc. Natl. Acad. Sci. USA, 96: 3496-3501, 1999. (Pubitemid 29168937)
20. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA, 96: 7196-7201, 1999. (Pubitemid 29299638)
21. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer, 37: 97-105, 2001. (Pubitemid 32119366)
22. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., and Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. USA, 97: 6780- 6784, 2000.
23. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA, 97: 6775-6779, 2000. (Pubitemid 30412790)
24. Synold, T. W., Dussault, I., and Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 7: 584-590, 2001. (Pubitemid 32448326)
25. Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S. I., Popescu, N., Kraemer, K. H., and Pommier, Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med., 7: 961-966, 2001. (Pubitemid 32756435)
26. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S. L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. (Bethesda), 81: 116-124, 1989. (Pubitemid 19031328)
27. Kuwazuru, Y., Yoshimura, A., Hanada, S., Utsunomiya, A., Makino, T., Ishibashi, K., Kodama, M., Iwahashi, M., Arima, T., and Akiyama, S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer (Phila.), 66: 868-873, 1990. (Pubitemid 20307917)
28. Erba, E., Bergamaschi, D., Bassano, L., Ronzoni, S., Di Liberti, G., Muradore, I., Vignati, S., Faircloth, G., Jimeno, J., and D'Incalci, M. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to ecteinascidin-743 (ET-743). Br. J. Cancer, 82: 1732-1739, 2000. (Pubitemid 30229586)
29. Akiyama, S. F. A., Hanover, J. A., Pastan, I., and Gottesman, M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol. Genet., 11: 117-126, 1985. (Pubitemid 15149285)
30. Debenham, P. G., Kartner, N., Siminovitch, L., Riordan, J. R., and Ling, V. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol. Cell Biol., 2: 881-889, 1982. (Pubitemid 12028244)
31. Sumizawa, T., Chen, Z. S., Chuman, Y., Seto, K., Furukawa, T., Haraguchi, M., Tani, A., Shudo, N., and Akiyama, S. I. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol. Pharmacol., 51: 399-405, 1997. (Pubitemid 27118475)
32. Kanzaki, A., Toi, M., Nakayama, K., Bando, H., Mutoh, M., Uchida, T., Fukumoto, M., and Takebayashi, Y. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn. J. Cancer Res., 92: 452-458, 2001. (Pubitemid 32427782)
33. Gottesman, M. M., and Pastan, I. The multidrug transporter, a double-edged sword. J. Biol. Chem., 263: 12163-12166, 1988.
34. Mickisch, G. H., Licht, T., Merlino, G. T., Gottesman, M. M., and Pastan, I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res., 51: 5417-5424, 1991.
35. Shen, D. W., Cardarelli, C., Hwang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I., and Gottesman, M. M. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem., 261: 7762-7770, 1986. (Pubitemid 17208699)
36. Shiraishi, N., Akiyama, S., Nakagawa, M., Kobayashi, M., and Kuwano, M. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res., 47: 2413-2416, 1987. (Pubitemid 17099206)
37. Tsuruo, T. I. H., Tsukagoshi, S., Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41: 1967-1972, 1981. (Pubitemid 11114605)
38. Scala, S., Budillon, A., Zhan, Z., Cho-Chung, Y. S., Jefferson, J., Tsokos, M., and Bates, S. E. Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J. Clin. Investig., 96: 1026-1034, 1995.
39. Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., Mohamed, A. N., Chelladurai, B., and Mohammad, R. M. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998. (Pubitemid 28213344)
40. Kaur, J., and Dey, C. S. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil. Biochem. Biophys. Res. Commun., 271: 615-619, 2000. (Pubitemid 30444676)
41. Vrana, J. A., and Grant, S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood, 97: 2105-2114, 2001. (Pubitemid 32239093)
42. Cornwell, M. M., and Smith, D. E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J. Biol. Chem., 268: 19505-19511, 1993. (Pubitemid 23270733)